Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/Bertilimumab> ?p ?o }
Showing triples 1 to 59 of
59
with 100 triples per page.
- Bertilimumab abstract "Bertilimumab is a human monoclonal antibody that binds to eotaxin-1, an important regulator of overall eosinophil function.It was discovered by Cambridge Antibody Technology using their phage display technology. Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders.In January 2007, CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc. iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications - a so-called 'search and development company'.iCo Therapeutics Inc. renamed the drug from CAT-213 to iCo-008 and, at that stage, planned to initiate a Phase II clinical trial in patients with vernal keratoconjunctivitis.In March 2008, iCo announced iCo-008 had been in 126 patients in Phase I and II clinical trials. The drug substance had been manufactured by Lonza, in its cGMP facilities in Slough, UK. Subsequently iCo moved the drug substance to a fill-finish site for the final stage of manufacturing. iCo reported that the iCo-008 drug product was within specifications and contained a high antibody yield.In June 2011, IMMUNE Pharmaceuticals (NASDAQ: IMNP) (Herzliya, Israel) in-licensed Bertilimumab from iCo for non-ophthalmic indications. IMMUNE is initiating Phase II clinical trials of Bertilimumab in inflammatory bowel disease (ulcerative colitis & Crohn's disease) in 2015 and 2016. Other indications planned for Bertilimumab development include severe asthma and liver disease (NASH).".
- Bertilimumab atcPrefix "none".
- Bertilimumab casNumber "375348-49-5".
- Bertilimumab wikiPageID "9124274".
- Bertilimumab wikiPageLength "3498".
- Bertilimumab wikiPageOutDegree "16".
- Bertilimumab wikiPageRevisionID "691417179".
- Bertilimumab wikiPageWikiLink CCL11.
- Bertilimumab wikiPageWikiLink Cambridge_Antibody_Technology.
- Bertilimumab wikiPageWikiLink Category:Experimental_medical_treatments.
- Bertilimumab wikiPageWikiLink Crohns_disease.
- Bertilimumab wikiPageWikiLink Eosinophil_granulocyte.
- Bertilimumab wikiPageWikiLink Herzliya.
- Bertilimumab wikiPageWikiLink Human.
- Bertilimumab wikiPageWikiLink Inflammatory_bowel_disease.
- Bertilimumab wikiPageWikiLink Keratoconjunctivitis.
- Bertilimumab wikiPageWikiLink Lonza_Group.
- Bertilimumab wikiPageWikiLink Monoclonal_antibody.
- Bertilimumab wikiPageWikiLink Phage_display.
- Bertilimumab wikiPageWikiLink Slough.
- Bertilimumab wikiPageWikiLink Ulcerative_colitis.
- Bertilimumab wikiPageWikiLink United_Kingdom.
- Bertilimumab wikiPageWikiLinkText "Bertilimumab".
- Bertilimumab atcPrefix "none".
- Bertilimumab casNumber "375348".
- Bertilimumab chemspiderid "none".
- Bertilimumab mabType "mab".
- Bertilimumab source "u".
- Bertilimumab target CCL11.
- Bertilimumab type "mab".
- Bertilimumab verifiedfields "changed".
- Bertilimumab verifiedrevid "459958463".
- Bertilimumab wikiPageUsesTemplate Template:Antineoplastic-drug-stub.
- Bertilimumab wikiPageUsesTemplate Template:Cascite.
- Bertilimumab wikiPageUsesTemplate Template:Chemspidercite.
- Bertilimumab wikiPageUsesTemplate Template:Drugbankcite.
- Bertilimumab wikiPageUsesTemplate Template:Drugbox.
- Bertilimumab wikiPageUsesTemplate Template:Immunosuppressants.
- Bertilimumab wikiPageUsesTemplate Template:Monoclonal-antibody-stub.
- Bertilimumab wikiPageUsesTemplate Template:Monoclonals_for_immune_system.
- Bertilimumab wikiPageUsesTemplate Template:Reflist.
- Bertilimumab subject Category:Experimental_medical_treatments.
- Bertilimumab hypernym Antibody.
- Bertilimumab type ChemicalSubstance.
- Bertilimumab type Drug.
- Bertilimumab type Antibody.
- Bertilimumab type Chemical.
- Bertilimumab type Drug.
- Bertilimumab type ChemicalObject.
- Bertilimumab type Thing.
- Bertilimumab type Q8386.
- Bertilimumab comment "Bertilimumab is a human monoclonal antibody that binds to eotaxin-1, an important regulator of overall eosinophil function.It was discovered by Cambridge Antibody Technology using their phage display technology. Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders.In January 2007, CAT licensed the drug for treatment of allergy disorders to iCo Therapeutics Inc. iCo Therapeutics Inc.".
- Bertilimumab label "Bertilimumab".
- Bertilimumab sameAs Q4895713.
- Bertilimumab sameAs برتيليموماب.
- Bertilimumab sameAs m.027yjvp.
- Bertilimumab sameAs Q4895713.
- Bertilimumab wasDerivedFrom Bertilimumab?oldid=691417179.
- Bertilimumab isPrimaryTopicOf Bertilimumab.